论文部分内容阅读
目的 :探讨 5 Fu联用MMC治疗大肠癌的体外药敏性及与临床化疗疗效的相关性。方法 :用MTT法测定联合化疗方案 5 Fu +MMC对 96例DukesB ,C期大肠癌的体外敏感性 ,统计其协同、相加、拮抗作用的发生率 ,用双盲法调查临床联用5 Fu和MMC治疗大肠癌的疗效 ,统计术后 3a复发率。结果 :88例大肠癌中联合用药方案体外检测结果存在拮抗、相加、协同作用。 4 2例联合用药中 ,有 15例体外检测结果发生拮抗作用 ,其中 8例 3a内复发 ;有 2 7例体外检测结果发生协同、相加作用 ,其中仅有 5例 3a内复发 ,前者复发率大于后者 ,统计结果有显著差异。结论 :5 Fu与MMC体外发生协同或相加作用组的联合化疗疗效优于体外发生拮抗作用组。
OBJECTIVE: To investigate the sensitivity of 5 FU combined with MMC in the treatment of colorectal cancer in vitro and its correlation with the efficacy of clinical chemotherapy. Methods: MTT was used to determine the sensitivity of 5 Fu + MMC to 96 cases of DukesB and C colorectal cancer in vitro. The synergistic, additive and antagonistic effects of 5 Fu + MMC were evaluated by double-blind method. And MMC for the treatment of colorectal cancer, statistics of 3a recurrence rate. Results: There were antagonistic, additive and synergistic effects of the combination therapy in 88 cases of colorectal cancer in vitro. In 42 cases of combination therapy, 15 cases had antagonistic effect in vitro, of which 8 cases relapsed in 3a. Twenty-seven cases had synergistic effect in vitro, of which only 5 cases had recurrence in 3a. The former had a relapse rate Greater than the latter, the statistics have significant differences. Conclusion: The combination chemotherapy of 5 Fu and MMC in vitro synergistically or additively has a better curative effect than that of antagonism in vitro.